G Chouinard
About
In The Last Decade
G Chouinard
98 papers receiving 2.6k citations
Peers
Comparison fields: 5 of 103
- Psychiatry and Mental health 1.6k
- Pharmacology 702
- Clinical Psychology 631
- Experimental and Cognitive Psychology 601
- Cellular and Molecular Neuroscience 514
Countries citing papers authored by G Chouinard
This map shows the geographic impact of G Chouinard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G Chouinard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G Chouinard more than expected).
Fields of papers citing papers by G Chouinard
This network shows the impact of papers produced by G Chouinard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G Chouinard. The network helps show where G Chouinard may publish in the future.
Co-authorship network of co-authors of G Chouinard
This figure shows the co-authorship network connecting the top 25 collaborators of G Chouinard. A scholar is included among the top collaborators of G Chouinard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G Chouinard. G Chouinard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 3 | |
| 2 | 30 | |
| 3 | 15 | |
| 4 | Beneficial effects of combined L-dopa and central anticholinergic in a patient with severe drug-induced parkinsonism and tardive dystonia. | 4 |
| 5 | 5 | |
| 6 | 97 | |
| 7 | 1 | |
| 8 | A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. | 56 |
| 9 | 44 | |
| 10 | 30 | |
| 11 | 44 | |
| 12 | 54 | |
| 13 | Long-term effects of L-dopa and procyclidine on neuroleptic-induced extrapyramidal and schizophrenic symptoms. | 13 |
| 14 | Death attributed to ventricular arrhythmia induced by thioridazine in combination with a single Contac C capsule. | 13 |
| 15 | [Electroconvulsive therapy in the treatment of depression]. | 1 |
| 16 | The effect of rubidium in schizophrenia. | 5 |
| 17 | Antiparkinsonian drug administration and plasma levels of penfluridol, a new long-acting neuroleptic. | 9 |
| 18 | Loxapine succinate in the treatment of newly admitted schizophrenic patients. | 3 |
| 19 | Alpha methyldopa-chlorpromazine interaction in schizophrenic patients. | 8 |
| 20 | Fluspirilene in the treatment of chronic schizophrenic patients. | 11 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.